Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Neurocrine Biosciences, Inc’s stock clocked out at $135.79, up 0.16% from its previous closing price of $135.57. In other words, the price has increased by $0.16 from its previous closing price. On the day, 1.4 million shares were traded. NBIX stock price reached its highest trading level at $137.075 during the session, while it also had its lowest trading level at $134.88.
Ratios:
To gain a deeper understanding of NBIX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.79. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.38. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.14.
On October 21, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $175.
On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $163.Truist initiated its Buy rating on July 21, 2025, with a $163 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 15 ’25 when Norwalk Leslie V sold 5,000 shares for $152.23 per share. The transaction valued at 761,144 led to the insider holds 7,429 shares of the business.
Norwalk Leslie V sold 1,190 shares of NBIX for $184,558 on Dec 16 ’25. The Director now owns 6,239 shares after completing the transaction at $155.09 per share. On Dec 15 ’25, another insider, Norwalk Leslie V, who serves as the Director of the company, bought 11,250 shares for $155.11 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBIX now has a Market Capitalization of 13539036160 and an Enterprise Value of 12903937024. As of this moment, Neurocrine’s Price-to-Earnings (P/E) ratio for their current fiscal year is 32.43, and their Forward P/E ratio for the next fiscal year is 19.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.04 while its Price-to-Book (P/B) ratio in mrq is 4.51. Its current Enterprise Value per Revenue stands at 4.81 whereas that against EBITDA is 22.638.
Stock Price History:
The Beta on a monthly basis for NBIX is 0.31, which has changed by -0.050618768 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, NBIX has reached a high of $160.18, while it has fallen to a 52-week low of $84.23. The 50-Day Moving Average of the stock is -6.96%, while the 200-Day Moving Average is calculated to be 3.14%.
Shares Statistics:
It appears that NBIX traded 1.01M shares on average per day over the past three months and 1121240 shares per day over the past ten days. A total of 99.70M shares are outstanding, with a floating share count of 97.07M. Insiders hold about 2.65% of the company’s shares, while institutions hold 98.53% stake in the company. Shares short for NBIX as of 1765756800 were 3939195 with a Short Ratio of 3.88, compared to 1763078400 on 3355702. Therefore, it implies a Short% of Shares Outstanding of 3939195 and a Short% of Float of 5.2600004.
Earnings Estimates
The dynamic stock of Neurocrine Biosciences, Inc (NBIX) is currently attracting attention from 15.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $1.99, with high estimates of $2.45 and low estimates of $1.77.
Analysts are recommending an EPS of between $7.58 and $6.47 for the fiscal current year, implying an average EPS of $6.92. EPS for the following year is $9.17, with 16.0 analysts recommending between $11.05 and $7.14.
Revenue Estimates
In. The current quarter, 24 analysts expect revenue to total $803.7M. It ranges from a high estimate of $829.11M to a low estimate of $760.8M. As of. The current estimate, Neurocrine Biosciences, Inc’s year-ago sales were $627.7MFor the next quarter, 24 analysts are estimating revenue of $779M. There is a high estimate of $848.49M for the next quarter, whereas the lowest estimate is $722.7M.
A total of 25 analysts have provided revenue estimates for NBIX’s current fiscal year. The highest revenue estimate was $2.88B, while the lowest revenue estimate was $2.8B, resulting in an average revenue estimate of $2.86B. In the same quarter a year ago, actual revenue was $2.36BBased on 24 analysts’ estimates, the company’s revenue will be $3.39B in the next fiscal year. The high estimate is $3.65B and the low estimate is $3.11B.
